Matches in Nanopublications for { ?s ?p "[This review focuses on ALK rearrangements in NSCLC, starting with the discovery of the EML4-ALK fusion oncogene, and culminating in the recent validation of ALK as a therapeutic target in patients with ALK-rearranged NSCLC.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- assertion description "[This review focuses on ALK rearrangements in NSCLC, starting with the discovery of the EML4-ALK fusion oncogene, and culminating in the recent validation of ALK as a therapeutic target in patients with ALK-rearranged NSCLC.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP215355.RAV_vL9b3O98rAttKvz4FMlizFUgGW4flkLuy-DZMDsqs130_assertion description "[This review focuses on ALK rearrangements in NSCLC, starting with the discovery of the EML4-ALK fusion oncogene, and culminating in the recent validation of ALK as a therapeutic target in patients with ALK-rearranged NSCLC.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP215355.RAV_vL9b3O98rAttKvz4FMlizFUgGW4flkLuy-DZMDsqs130_provenance.
- assertion description "[This review focuses on ALK rearrangements in NSCLC, starting with the discovery of the EML4-ALK fusion oncogene, and culminating in the recent validation of ALK as a therapeutic target in patients with ALK-rearranged NSCLC.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP869729.RAiboyIshS_JCO5yeyLITipqGy7LHKLE_Xhy4Sx5ZzQ4Q130_assertion description "[This review focuses on ALK rearrangements in NSCLC, starting with the discovery of the EML4-ALK fusion oncogene, and culminating in the recent validation of ALK as a therapeutic target in patients with ALK-rearranged NSCLC.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP869729.RAiboyIshS_JCO5yeyLITipqGy7LHKLE_Xhy4Sx5ZzQ4Q130_provenance.
- NP869727.RANcd7r3dP9MTZip-CzlM-uuP5u1Mp2kHjQTD7dvJyfEk130_assertion description "[This review focuses on ALK rearrangements in NSCLC, starting with the discovery of the EML4-ALK fusion oncogene, and culminating in the recent validation of ALK as a therapeutic target in patients with ALK-rearranged NSCLC.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP869727.RANcd7r3dP9MTZip-CzlM-uuP5u1Mp2kHjQTD7dvJyfEk130_provenance.